Search the Newsreel

Vivani Medical, Inc. (VANI) stock price, news, quote and history

Vivani Medical, Inc. (VANI) is a clinical-stage biopharmaceutical company focused on developing miniaturized subdermal drug implants for chronic diseases. The article provides a comprehensive overview of VANI's stock performance, including its current price, historical data, key financial metrics, and analyst ratings. It also details …

Earnings call transcript: Roivant misses Q1 2026 EPS as pipeline build accelerates

Roivant Sciences reported a wider-than-expected first-quarter loss, with EPS of -$0.75 against an analyst forecast of -$0.60, as the company continued heavy spending on R&D and commercial preparation. Despite the miss, management framed the period as a "calm before the storm," anticipating a "jam-packed …

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Artiva Biotherapeutics reported its Q2 2026 financial results, highlighting significant progress with its lead program, AlloNK. The company announced positive clinical data for AlloNK in treating refractory rheumatoid arthritis (RA) and other autoimmune diseases, received FDA RMAT designation for AlloNK in refractory RA, and …

ARTV: Strong clinical progress, FDA RMAT, and $300M raise set up Phase 3 launch and cash runway to 2029

Artiva Biotherapeutics (ARTV) has demonstrated strong clinical progress for its AlloNK therapy in autoimmune diseases, showing 71% ACR50 response in refractory RA patients with good safety. The FDA's RMAT designation and a recent $300 million capital raise are supporting the launch of a Phase …

Certain Stock Options of Artiva Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-AUG-2026.

Certain stock options of Artiva Biotherapeutics, Inc. will be under a 91-day lock-up period, starting from May 8, 2026, and ending on August 7, 2026. During this period, officers, directors, and affiliated funds are restricted from selling, offering, or otherwise disposing of these stock …

Roivant Sciences Releases Q1 2026 Financial Results

Roivant Sciences Ltd. reported a narrowed Q1 2026 diluted EPS loss of -$0.26, a 21.2% improvement year-over-year, despite a net loss of $189.8M and a revenue decline to $1.4M. The clinical-stage biopharmaceutical company continues to focus on advancing its drug pipeline, with Wall Street …

Roivant Sciences earnings beat by $0.04, revenue fell short of estimates

Roivant Sciences (NASDAQ: ROIV) reported second-quarter earnings per share of $-0.260, surpassing analyst estimates by $0.04. However, the company's revenue of $1.44 million fell short of the consensus estimate of $2.32 million. Despite the revenue miss, Roivant Sciences' stock has shown strong performance, increasing …

Artiva Biotherapeutics, Inc. (ARTV) Stock Price, News, Quote & History

This article provides a comprehensive overview of Artiva Biotherapeutics, Inc. (ARTV) stock, including its current price, historical performance, and key financial data. It highlights the company's focus on developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers, detailing its lead product candidates …

LivaNova PLC (LIVN) (Q2 2026) Earnings Call Highlights: Record Revenue and EPS, Raised Guidance ...

LivaNova PLC (LIVN) reported record revenue of $391 million and adjusted EPS of $1.26 for Q2 2026, driven by strong growth in both Cardiopulmonary and Epilepsy segments. The company raised its full-year 2026 revenue guidance to 8%-9% growth and adjusted EPS guidance to $4.30-$4.40, …

FMR LLC (LIVN) discloses 5.8% LivaNova stake in Schedule 13G filing

FMR LLC has filed a Schedule 13G, disclosing a beneficial ownership of 5.8% in LivaNova PLC (LIVN) common stock, amounting to 3,210,395.27 shares as of June 30, 2026. Both FMR LLC and Abigail P. Johnson reported this stake, with FMR LLC holding sole voting …

LivaNova PLC Stock 12‑Month Price Target Raised to $88.78, Implies 4% Upside

LivaNova PLC (LIVN) has seen its average 12-month price target increased from $86.78 to $88.78 by 9 analysts, with individual forecasts ranging from $75 to $95. This new target suggests a potential upside of approximately 4% from its closing price on August 4. The …

Carnival Corporation Sets New Greenhouse Gas Emissions Intensity Reduction Target

World's largest cruise company reinforces GHG intensity goal with new 25% reduction target by 2029, raising previous goal by five percentage points and accelerating timeline by one year New target follows company achieving original 2030 goal five years early thanks to its comprehensive decarbonization …

LivaNova Sees Solid Demand in Both Cardiopulmonary and Neuromodulation

B. Riley Adjusts Price Target on trivago to $8 From $6, Maintains Buy Rating

B. Riley has increased its price target for trivago (TRVG) shares to $8 from $6, while reiterating a Buy rating on the stock. This adjustment reflects a positive outlook on the online hotel search platform. The article also notes other recent analyst actions and …

Shivalik Rasayan former director Sanjay Bansal sells ₹1.25 crore stake

Ivanhoe Mines Provides Clarification to Reuters' Article Announcing the Ban of Copper and Cobalt Concentrate Exports from the DRC

Johannesburg, South Africa--(Newsfile Corp. - August 6, 2026) - A story was published by British news agency Reuters today, August 6, 2026, announcing the ban on copper and cobalt concentrates from the Democratic Republic of the Congo (DRC). Ivanhoe Mines clarifies that a ban …

Roivant Sciences Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2026

Roivant Sciences Ltd. reported its financial results for the first quarter ended June 30, 2026. The company experienced a decrease in sales to USD 1.44 million from USD 2.17 million in the prior year. Despite lower sales, the net loss narrowed to USD 189.84 …

Roivant Sciences Q1 2027 Earnings Call Transcript

Roivant Sciences held its Q1 2027 earnings call, highlighting significant progress and an exciting pipeline for the coming year. The company is on track for the late September launch of brepocitinib for dermatomyositis and has initiated a Phase III study for cutaneous sarcoidosis. Roivant …

Semaglutide implant trial doses all 20 participants; data expected in November

Vivani Medical announced the successful dosing of all 20 participants in its SLIM-1 Phase 1 trial for NPM-139, a miniature, subdermal semaglutide implant designed for chronic weight management. The trial compares low-dose NPM-139 with Wegovy and focuses on safety, tolerability, pharmacokinetics, and weight change. …

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical announced the successful dosing of all participants in its SLIM-1 Phase 1 trial for NPM-139, a miniature, subdermal semaglutide implant for chronic weight management. The trial involves 20 GLP-1 naïve participants in Australia and aims to assess the safety, tolerability, and pharmacokinetics …

Activate Energy Acquisition Corp. Revenue Breakdown – NASDAQ:AEAQU

This article provides a revenue breakdown for Activate Energy Acquisition Corp. (NASDAQ: AEAQU), accessible through TradingView. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segments, with data provided by ICE Data Services and FactSet. The page also highlights …

Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q1 Revenue $1.4M, vs. FactSet Est of $2.1M

Roivant Sciences Ltd. reported Q1 revenue of $1.4 million, which fell short of FactSet's estimated $2.1 million. This financial update indicates that the biopharmaceutical company's revenue performance for the quarter did not meet analyst expectations. The article provides a snapshot of the company's recent …

Roivant Sciences (NASDAQ: ROIV) details $771.6M Moderna settlement windfall

Roivant Sciences (NASDAQ: ROIV) reported a net loss of $290.6 million for the quarter ended June 30, 2026, driven by increased research and development expenses. The company's liquidity was significantly bolstered by a $771.6 million litigation settlement receivable from Moderna, which was collected in …

Roivant Sciences Ltd. (ROIV) Tops Q1 EPS by 4c

Roivant Sciences Ltd. (ROIV) reported its Q1 earnings, beating analyst EPS estimates by $0.04 with a reported EPS of ($0.26) against an estimated ($0.30). However, the company's revenue for the quarter came in at $1.44 million, falling short of the consensus estimate of $2.32 …

Workiva (WK) Stock Shrugs Off Profit Breakthrough As Valuation Debate Deepens

Workiva's stock saw a muted reaction despite reporting strong Q2 2026 earnings, including a move to profitability and significant margin improvements. The company's revenue reached US$255.29m, and basic EPS hit US$0.84, while non-GAAP operating margin improved significantly to 16.8%. The article explores the debate …

LivaNova Plans for Early 2027 Launch of Aura6000 for Obstructive Sleep Apnea

LivaNova, a medical-device firm, plans an early 2027 launch for its Aura6000 device designed to treat obstructive sleep apnea. The company employs an innovation strategy focused on differentiated products and strong commercialization through salesforce relationships, similar to larger competitors. This strategy aims to create …

Shiva Mills Share: நஷ்டத்திலிருந்து லாபத்திற்குத் திரும்பிய Shiva Mills! Q1 FY27 முடிவுகள் இதோ!

trivago (NasdaqGS:TRVG) Stock Faces Profit Questions Despite Stronger Revenue

Trivago's stock (NasdaqGS:TRVG) declined despite a 21% increase in Q2 revenue, reaching €168.4 million, and the company returning to profitability over the trailing twelve months with €13.1 million in earnings. However, a quarterly net loss of €5.2 million and concerns about marketing spend and …

Clarivate Insider Sold Shares Worth $4,829,859, According to a Recent SEC Filing

An insider at Clarivate Plc reportedly sold shares valued at $4,829,859, as per a recent SEC filing. The article, published by MT Newswires, provides this financial transaction detail but restricts the full content to members. Clarivate Plc is a provider of transformative intelligence solutions …

Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development

Expanded capabilities across Cortellis portfolio help life sciences organizations turn trusted intelligence into action and accelerate decision making across the research and development lifecycle LONDON, Aug. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the expansion …

Trivago N.V. ADS (NASDAQ:TRVG) Price Target Raised to $8.00

Susquehanna has increased its price target for Trivago N.V. ADS (NASDAQ:TRVG) from $3.25 to $5.50, while maintaining a "neutral" rating, suggesting a potential upside of 6.18%. Despite this, analyst sentiment remains cautious, with a consensus rating of "Reduce" and an average price target of …

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

Shiva Mills Q1 Results: Net Profit Rises To ₹2.83 Crore, Revenue Up

FMR LLC and Abigail Johnson report 5.7% Ivanhoe Electric (IE) stake

LivaNova (LIVN) Stock Drops As Cash Flow Concerns Cut Through Profit Surge

LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised